No Data
Yantai Zhenghai Bio-Tech (300653.SZ): Has repurchased 0.65% of shares.
Yantai Zhenghai Bio-Tech (300653.SZ) announced on September 3 that as of August 31, 2024, the company repurchased 1,177,350 shares of its own stock through a special securities account for stock repurchase, accounting for 0.6541% of the company's total share capital. The highest fill price was 24.83 yuan per share, and the lowest fill price was 18.43 yuan per share. The total amount paid was 24.9983 million yuan (excluding transaction costs).
Yantai Zhenghai Bio-Tech (300653.SZ): The application for medical instruments registration has been accepted.
Yantai Zhenghai Bio-Tech (300653.SZ) announced on August 19 that it has recently received a notification of acceptance of the medical device registration application issued by the Shandong Provincial Drug Administration. The product is named as non-absorbable surgical suture. Surgical sutures are mainly used for the sewing and ligation of human tissues, and according to their biodegradability, they are divided into two categories: non-absorbable surgical sutures and absorbable surgical sutures.
Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Market Cap up CN¥547m Last Week, Benefiting Both Individual Investors Who Own 43% as Well as Insiders
Yantai Zhenghai Bio-Tech (300653.SZ): The summary report for the calcium-silicon biological ceramic bone repair material has been completed, and it will be submitted for registration in the second half of the year.
On August 8th, Gelon Hui reported that Yantai Zhenghai Bio-Tech (300653.SZ) announced at an investor relations event that as of now, the company's oral pipeline biological repair film is in the stage of registration and compensation, and the calcium-silicon biological ceramic bone repair material has completed the summary report and will be submitted for registration in the second half of the year. These two products are upgrades and iterations of existing products, and the company hopes to further enhance the product power of the membrane powder combination through the layout of new products, thus driving the sales growth of the oral product portfolio.
Yantai Zhenghai Bio-Tech (300653.SZ): The main products are block orders for oral repair films and bone repair materials, and currently neither of the two products are involved in centralized procurement.
Yantai Zhenghai Bio-Tech (300653.SZ) stated in an investor relations activity that the company's block orders for the dental industry include oral restoration membrane and bone repair materials. Currently, these two products are not involved in joint procurement. Joint procurement is affected by various factors and the company will closely monitor the promotion and implementation of relevant joint procurement policies.
Yantai Zhenghai Bio-tech (300653.SZ): The policy of centralized procurement of dental implants has been fully implemented for more than a year, and the overall cost of a single conventional dental implant has been greatly reduced.
Zhenghai Bio-Tech (300653.SZ) stated in an investor relations event on August 8th that as of April 2024, the centralized procurement policy for dental implants has been fully implemented for over a year, leading to a significant decrease in the overall cost of conventional oral implants and a noticeable alleviation of patients' medical burden. With the implementation of the procurement policy, the price gap between public and private oral medical institutions has narrowed and the competition in the private oral industry has become increasingly intense. Although the implant repair materials have not been included in the scope of centralized procurement, they have also been affected by demand fluctuations and downstream cost control in the first half of the year. The company optimized its application for dental-related products in the field of implants.
Little Excitement Around Yantai Zhenghai Biotechnology Co., Ltd.'s (SZSE:300653) Earnings As Shares Take 29% PoundingNo Data
